Co-injection of recombinant Rv0888NS/MS with an MPO inhibitor remarkably decreased recombinant Rv0888NS/MS-induced pulmonary hemorrhage, infiltration of inflammatory cells, and release of inflammatory cytokines (IL-6, TNF-α and IL-1β). This evidence concerns the gene MPO and Pulmonary hemorrhage.